111 related articles for article (PubMed ID: 17287635)
21. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Mazokopakis EE; Vrentzos GE; Ganotakis ES
Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
[TBL] [Abstract][Full Text] [Related]
22. [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
Vorob'eva NM; Panchenko EP; Kirienko AI; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Andriiashkin VV; Leont'ev SG
Ter Arkh; 2009; 81(9):57-61. PubMed ID: 19827655
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
Maximiliano CL; Jaime GC; Erika MH
Thromb Res; 2023 Feb; 222():43-48. PubMed ID: 36565679
[TBL] [Abstract][Full Text] [Related]
24. Prolonged acenocoumarol treatment in patients with venous thromboembolic disease from a rural area.
Calvo-Romero JM
South Med J; 2007 Jul; 100(7):725. PubMed ID: 17639755
[No Abstract] [Full Text] [Related]
25. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
[TBL] [Abstract][Full Text] [Related]
26. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study.
Pérez-de-Llano LA; Leiro-Fernández V; Golpe R; Núñez-Delgado JM; Palacios-Bartolomé A; Méndez-Marote L; Colomé-Nafria E
Blood Coagul Fibrinolysis; 2010 Dec; 21(8):744-9. PubMed ID: 20885298
[TBL] [Abstract][Full Text] [Related]
27. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.
Wawrzyńska L; Tomkowski WZ; Przedlacki J; Hajduk B; Torbicki A
Pathophysiol Haemost Thromb; 2003; 33(2):64-7. PubMed ID: 14624046
[TBL] [Abstract][Full Text] [Related]
28. Short-term clinical outcome after acute symptomatic pulmonary embolism.
Conget F; Otero R; Jiménez D; Martí D; Escobar C; Rodríguez C; Uresandi F; Cabezudo MA; Nauffal D; Oribe M; Yusen R
Thromb Haemost; 2008 Nov; 100(5):937-42. PubMed ID: 18989541
[TBL] [Abstract][Full Text] [Related]
29. Individualized compared with conventional dosing of enoxaparin.
Barras MA; Duffull SB; Atherton JJ; Green B
Clin Pharmacol Ther; 2008 Jun; 83(6):882-8. PubMed ID: 17928819
[TBL] [Abstract][Full Text] [Related]
30. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin.
Kothari SN; Lambert PJ; Mathiason MA
Am J Surg; 2007 Dec; 194(6):709-11. PubMed ID: 18005758
[TBL] [Abstract][Full Text] [Related]
31. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
32. Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
Hebbeler SL; Marciniak CM; Crandall S; Chen D; Nussbaum S; Mendelewski S
J Spinal Cord Med; 2004; 27(3):236-40. PubMed ID: 15478526
[TBL] [Abstract][Full Text] [Related]
33. [Treatment with oral anticoagulants (acenocoumarol): influence of the initial doses in the incidence of hemorrhagic and thromboembolic episodes].
Amian A; Rodríguez JN; Muñiz R; Diéguez JC; Cañavate M; Fernández-Jurado A; Martino ML; Prados D
Sangre (Barc); 1994 Dec; 39(6):413-6. PubMed ID: 7855691
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
Nieto JA; Camara T; Gonzalez-Higueras E; Ruiz-Gimenez N; Guijarro R; Marchena PJ; Monreal M;
Thromb Haemost; 2008 Nov; 100(5):789-96. PubMed ID: 18989522
[TBL] [Abstract][Full Text] [Related]
36. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
37. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
38. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
Tran H; McRae S; Ginsberg J
Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997
[TBL] [Abstract][Full Text] [Related]
40. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
LaPointe NM; Chen AY; Alexander KP; Roe MT; Pollack CV; Lytle BL; Ohman ME; Gibler BW; Peterson ED
Arch Intern Med; 2007 Jul; 167(14):1539-44. PubMed ID: 17646609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
